Update on Probiodrug’s Patents

Status of opposition OF EP 0896538 During May 11-12, 2004, oral hearings were held at the European Patent Office in Munich concerning the oppositions filed against […]

First native DP IV-structure solved

In a fruitful collaborative effort between the Max-Planck-Institute of Biochemistry, Proteros Biostructures GmbH, both located in Martinsried, and probiodrug AG, Halle (Saale), the sequence and 1.8 […]

Further US-patent issued

Halle (Saale), Germany // Probiodrug demonstrates first long-term effect of DP IV inhibition in the treatment of type 2 diabetes: normalisation of fasting blood glucose and […]